The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 2)
Therapeutics Development Initiative, 2006
The principal feature of Parkinson's disease is a progressive death of dopamine neurons in the substantia nigra. Pharmacological therapies that enhance dopamine activity effectively treat the rigidity and bradykinesia (slowing and difficulty initiating movement) associated with PD. However, the efficacy of current dopaminergic therapies diminishes over time because of the associated development of...
Community Fast Track, 2003
Gradual slowing of movement in Parkinson's disease (PD) is due to the steady decline in brain levels of dopamine, a chemical signal that facilitates normal movement. Our most effective medications for the treatment of PD (namely, L-dopa and dopamine agonists) work by replacing the lost dopamine. However they can produce side effects of involuntary jerking and twisting movements known as dyskinesia...
Researchers: Michael A. Schwarzschild, MD, PhD